Early Access — free while we kick the tires
EdgarHawk

Hagan Joseph P

Chief Executive Officer

Director Officer
1 filing analyzed · 1 company · Latest 2025-01-31

Companies

Company Buys Sells Direction
Regulus Therapeutics Inc. RGLS 1 0 Net buying

Activity

January 2025
high
Buy
50,000 shares
$54,260
Significance 7/10

CEO Joseph P Hagan bought 50.0K shares of RGLS at $1.09 on 2025-01-30; stock down 65.3% from 52-week high.

Chief Executive Officer Joseph P Hagan purchased 50,000 shares at $1.09, increasing his holdings by 23.7% to 260.8K shares post-transaction. The purchase occurs in the context of severe stock weakness: RGLS has declined 65.3% from its 52-week high of $2.88 and 36.7% over the past 30 days. The company reported zero revenue in the latest quarter and net income of $-14.1M for the full fiscal year, with annual revenue growth of -100.0%. While an open-market equity purchase by the CEO creates an observable fact in the public record, investors should evaluate this transaction against the company's operational deterioration rather than treating it in isolation from the fundamental backdrop.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access